Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease

Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease

Sodium-glucose cotransporter inhibitors updated their position in the therapy of patients with type 2 diabetes mellitus due to proven nephro- and cardioprotective effects. The DAPA-CKD study, performed among individuals with CKD of various etiologies, was also conducted in a mixed population, includ...

Full description

Bibliographic Details
Main Authors: Minara S. Shamkhalova, Olga Y. Sukhareva, Marina V. Shestakova
Format: Article
Language:Russian
Published: "Consilium Medicum" Publishing house 2022-11-01
Series:Терапевтический архив
Subjects:
sglt-2 inhibitor
dapagliflozin
dapa-ckd study
chronic kidney disease
Online Access:https://ter-arkhiv.ru/0040-3660/article/viewFile/108317/pdf

Similar Items

Similar Items